Development of a digital tool to assess the risk of thromboembolic disease and prescription of prophylactic anti-thrombotic therapy in oncologic patients.

232Background: Thromboprophylaxis for oncologic patients represents a huge challenge. The existence of more specific guidelines for anti-thrombotic therapy in hospitalized and ambulatory oncologic patients is an unmet need. Methods: We present an observational, descriptive, retrospective and transversal study, from January 2012 to December 2016, all the oncologic patients hospitalized for any cause in the Hospital Espanol de Mexico were included. We reviewed clinical files and obtained demographic and disease characteristics necessary to stratify the risk of thromboembolism using the Khorana score. A bivariate analysis was done between the risk of thromboembolism and the use of thromboprophylaxis and a multivariate analysis to identify the reproducibility of Khorana score in Mexican patients. Results: Of the 1048 patients included in the study, 65.6% (688 patients) were categorized by the Khorana score with intermediate risk of thromboembolism, 26% (273 patients) with low risk and 8.4% (87 patients) with ...